16th Annual Wall Street Analyst Forum Presenting Company
16th Annual Wall Street Analyst Forum NEW YORK--(BUSINESS WIRE)--Feb. 28, 2005 The 16th Annual Wall Street Analyst Forum takes place Feb. 28th through March 2nd at the Roosevelt Hotel in New York City.
For in-depth information about this event visit: http://www.analyst-conference.com/.
Below are profiles from the 16th Annual Wall Street Analyst Forum Presenting Companies; breaking news releases are available at http://www.tradeshownews.com, Business Wire's trade show, conference and event news resource. Business Wire is the official news wire service for the 16th Annual Wall Street Analyst Forum.
Company: Anworth Mortgage Asset Corporation Date of Presentation: February 28, 2005 Time of Presentation: 9:40 a.m. Eastern Standard Time Investor Relations Contact: John T. Hillman, Director of Investor Relations Phone: 310-255-4438 E-mail: firstname.lastname@example.org Web Site: www.anworth.com Link to Webcast: http://www.vcall.com/CEPage.asp?ID=90670 Anworth Mortgage (NYSE:ANH) is a Real Estate Investment Trust that invests primarily in mortgage-backed securities issued by U.S. agencies and secured by adjustable-rate and fixed-rate single-family residential mortgages. Through its Belvedere Trust Mortgage Corporation subsidiary, Anworth also invests in high quality jumbo single-family adjustable-rate mortgage loans acquired and financed through securitizations. The return on stockholders' equity is principally the difference between the yield on the interest-earning assets and the cost of the financing activities which are primarily short-term collateralized borrowings and longer-term collateralized securitizations. Anworth commenced its operations on March 17, 1998 upon the completion of its initial public offering of common stock at $9.00 per share. In 2004, Anworth also issued an 8-5/8% Series A Cumulative Preferred Stock at $25.00 per share which also trades on the NYSE. At year-end 2004, the Company's assets were approximately $7,316,000,000. From the IPO date to year-end 2004, Anworth has provided its common stock shareholders with dividend income of $7.75 per share. Anworth is a member of the Russell 2000 Index. Company: BIO-key International Date of Presentation: March 1, 2005 Time of Presentation: 2 PM Investor Relations Contact: Bud Yanak Phone: 732-359-1113 E-mail: email@example.com Web Site: www.bio-key.com BIO-key develops and delivers advanced identification solutions and information services to law enforcement departments, fire/emergency medical service agencies and other government and private sector customers. BIO-key's mobile wireless technology provides first responders with critical, reliable, real-time data and images from local, state and national databases. BIO-key's superior, scalable, cost-effective and easy-to-deploy biometric finger identification technology accurately identifies and authenticates users to improve security, convenience and privacy while reducing identity theft. Today, more than 2,500 police, fire and emergency services departments in North America depend on BIO-key solutions, making us the leading supplier of mobile and wireless solutions for public safety worldwide. BIO-key HAS THE ANSWER The answer to increased security while improving user convenience! Eliminating passwords, which can be lost or compromised! Eliminating help desk and administration costs associated with passwords! Improving user convenience -- with the simple touch of a finger, users quickly, easily enter a facility or log onto a computer/domain. Company: Candela Corporation Date of Presentation: March 2, 2005 Time of Presentation: 11:00 a.m. (ET) Investor Relations Contact: Paul Broyer Phone: 508-358-7637, ext. 435 E-mail: firstname.lastname@example.org Web Site: www.candelalaser.com Link To Webcast: www.vcall.com/CEPage.asp?ID=90211 Candela Corporation, an ISO-9001 certified company, is a pioneer in the development and commercialization of advanced aesthetic laser systems and intense pulsed light devices that allow physicians and personal care practitioners to treat a wide variety of cosmetic and medical conditions. Candela's extensive product line -- the most comprehensive and technologically sophisticated aesthetic devices in the industry -- is used by dermatologists, plastic surgeons, family practitioners, OB/GYNs, and general and vascular surgeons for hair removal, wrinkle reduction, as well as the treatment of vascular and pigmented lesions, tattoos, acne, and acne scars. Founded near Boston in 1970, the company markets and services its products in over 64 countries from offices and distributors in the United States, Europe, Japan, China, and other Asian locations. Candela established the aesthetic laser market 16 years ago, and currently has an installed base of 8,000 lasers worldwide. Candela is an Equal Opportunity and Affirmative Action Employer (Male/Female/Handicapped/Veteran). Company: Colonial Properties Trust Date of Presentation: February 28, 2005 Time of Presentation: 10:20 am Investor Relations Contact: Barbara Pooley Phone: 704-376-1774 E-mail: email@example.com Web Site: www.colonialprop.com Link To Webcast: http://www.vcall.com/CEPage.asp?ID=90671 Colonial Properties Trust is a diversified real estate investment trust (REIT) that, through its subsidiaries, owns a portfolio of multifamily, office and retail properties where you live, work and shop in the Sunbelt region of the United States. As a self-administered, self-managed REIT, Colonial Properties performs development, acquisition, management, leasing and brokerage services for its portfolio and properties owned by third parties. Founded in 1970 and headquartered in Birmingham, Alabama, Colonial Properties Trust completed its initial public offering in September 1993. The Company, which is included in the S&P SmallCap 600 Index, is listed on the New York Stock Exchange under the symbol "CLP" and has a current market capitalization in excess of $3.5 billion. At year end 2004, the Company's portfolio included 29,100 apartment units, 6.8 million square feet of office space and 15.6 million square feet of retail shopping space located from Virginia to Arizona. Company: Emisphere Technologies, Inc. Date of Presentation: March 1, 2005 Time of Presentation: 9:40 am ET Investor Relations Contact: Gillian Racine Phone: 914-593-8332 E-mail: firstname.lastname@example.org Web Site: www.emisphere.com Link To Webcast: http://www.vcall.com/CEPage.asp?ID=90679 Emisphere Technologies, Inc. is a biopharmaceutical company pioneering the oral delivery of otherwise injectable drugs. Emisphere's business strategy is to develop oral forms of injectable drugs, either alone or with corporate partners, by applying its proprietary eligen(R) technology to those drugs or licensing its eligen(R) technology to partners who typically apply it directly to their marketed drugs. Emisphere's eligen(R) technology has enabled the oral delivery of proteins, peptides, macromolecules and charged organics. Emisphere and its partners have advanced oral formulations or prototypes of salmon calcitonin, Heparin, insulin, parathyroid hormone, human growth hormone and cromolyn sodium into clinical trials. Emisphere has strategic alliances with world-leading pharmaceutical companies. For further information, please visit http://www.emisphere.com. Company: GenOil Inc. Date of Presentation: March 2nd Time of Presentation: 11:40am Investor Relations Contact: Candice Beaumont Phone: 212-688-9606 E-mail: CSBeaumont@genoil.net Web Site: www.genoil.net GenOil's technologies represent either breakthrough or innovative technological approaches to existing oil and gas production or refinery problems. GenOil's solutions can be readily integrated into conventional systems to increase productivity, reduce both capital and operating costs, thereby providing a rapid payback. GenOil currently owns 12 technologies and intellectual property that are protected under 19 patents or patents pending. GenOil's primary technology is the hydroconversion upgrader (GHU). The GHU upgrading process can produce approximately 2 million barrels a day of new oil from rejected carbon, and can convert 13 million barrels of heavy oil bottoms or residues from refining to lighter oil for use in making gasoline. Those fifteen million barrels of oil can replace the entire production of light oil from the Persian Gulf and solve the shortage in gasoline. GenOil's patented hydrogenation process converts heavy oil fractions into lighter fractions, resulting in 25% greater output of oil from refineries and significant cost savings. With US refineries running at capacity, together with finite world oil supplies this technology could be one of the most valuable innovations of the century. Company: Hana Biosciences, Inc. Date of Presentation: February 28, 2005 Investor Relations Contact: Russell Skibsted Phone: 650-588-6464 E-Mail: email@example.com Website: www.hanabiosciences.com Hana Biosciences, Inc. (OTCBB:HNAB), is a biopharmaceutical company headquartered in South San Francisco. The company acquires, develops, and commercializes innovative products for the treatment of important unmet medical needs in cancer. Hana has three pipeline products: Ondansetron Lingual Spray (OLS) for chemotherapy-induced nausea and vomiting is on target to start producing revenues in 2007. PT-523 for non-small cell lung cancer, cervical cancer and acute lymphocytic leukemia, was licensed from Harvard and is in clinical trials there. IPdR, a novel radiosensitizer, for pancreatic, colorectal, liver, and brain cancers was licensed from Yale University and The Research Foundation of the State University of New York at Buffalo. Hana Biosciences is committed to creating value by building a world-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture. Additional information on Hana Biosciences can be found at www.hanabiosciences.com. Company: I-trax, Inc. Date of Presentation: March 1, 2005 Time of Presentation: 12:30pm Investor Relations Contact: Chris Witty (Lippert/Heilshorn) Phone: 212-201-6609 E-mail: firstname.lastname@example.org Web Site: www.i-trax.com Link To Webcast: http://www.vcall.com/CEPage.asp?ID=90210 I-trax is a leading integrated health and productivity management company formed by the merger of I-trax Health Management Solutions and CHD Meridian Healthcare. We provide on-site health and pharmacy services as well as disease management and wellness programs that improve overall health while reducing the cost of care. We are the only comprehensive solution specifically designed for every individual regardless of location. We help individuals stay healthy, productive and at work. Our focus is on the prevention and management of disease and illness, lowering the direct and indirect costs of health related benefits, while at the same time improving individual health, satisfaction and productivity. Our health management teams consist of over 1,200 healthcare professionals, including physicians, nurses and allied health professional. We serve nearly 100 clients at over 185 locations nationwide. Our clients include self-insured employers, health plans and government organizations. Company: mPhase Technologies, Inc. Date of Presentation: Monday, February 28, 2005 Time of Presentation: 2:40 p.m. (Eastern) Investor Relations Contact: Mary K. Whelan Phone: 973-256-3737 Ext. 110 E-mail: email@example.com Web Site: www.mphasetech.com Webcast: http://www.vcall.com/CEPage.asp?ID=90668 mPhase Technologies (OTCBB:XDSL) develops and commercializes next-generation solutions for telecommunications and nanotechnology applications. mPhase is delivering leading edge components and test equipment for digital subscriber networks (DSL). mPhase operates as a small, high growth, low overhead business by leveraging technologies licensed from major technological powerhouses. Examples include work with Lucent's Bell Labs in nanobatteries and IP video. The Company also benefits from its close working relationship with Lucent's worldwide sales channels and services business. The Company is pursuing a strategy of generating revenues and gross profits from its currently commercialized products while developing other high-potential technologies that it plans to commercialize in the future. Company: NovaDel Pharma Date of Presentation: March 1, 2005 Time of Presentation: 8:20 a.m. Investor Relations Contact: Erik Lux Phone: 212-825-3210 e-mail: firstname.lastname@example.org Web Site: www.novadel.com Link To Webcast: http://www.vcall.com/CEPage.asp?ID=90210 NovaDel Pharma Inc. is a specialty pharmaceutical company that is developing a novel drug-delivery system for both prescription and over-the-counter therapeutics. The Company's proprietary technology uses a lingual spray to rapidly deliver drugs into the systemic circulation. The technology can be applied to a variety of drugs in the Rx, OTC and veterinary therapeutic areas. The delivery of a therapeutic agent through the oral mucosa may lead to a faster onset of action and avoids degradation in the GI tract. Lingual sprays generally permit administration of a lower dose of the active ingredient compared with tablet formulations of the same drug due to efficient mucosal absorption and avoidance of the GI tract and hepatic first-pass effects. Drugs administered in a spray form to the oral mucosa have the potential for a) faster onset of action, b) improved safety profile, and c) enhanced patient compliance. Company: Nutra Pharma Corporation Date of Presentation: Monday, February 28th Time of Presentation: 11:40am Investor Relations Contact: Rik J Deitsch Phone: 954-509-0911 E-mail: email@example.com Web Site: www.nutrapharma.com Link To Webcast: http://www.vcall.com/CEPage.asp?ID=90209 Nutra Pharma Corporation (OTCBB:NPHC) is a biotechnology holding company and incubator. The Company's minority-owned subsidiary, ReceptoPharm, Inc., is developing technologies for the development of drugs for HIV, AMN and Multiple Sclerosis ("MS"). The Company's other holding, Infectech, Inc., is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB). Nutra Pharma has begun the acquisition of Portage Biomed, a biotechnology research company developing novel drug delivery systems to be used with various drug therapies in the treatment of diseases. Their primary research is in creating innovative systems for the safer and more efficient distribution of existing chemotherapeutic agents in the treatment of cancer. Nutra Pharma expects to complete its acquisition of Portage Biomed by the second quarter of 2005. Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena. Company: PNM Resources Date of Presentation: Wednesday, March 2, 2005 Time of Presentation: 11:40 a.m. EST Investor Relations Contact: Lisa Riser, executive director Phone: 505-350-2787 E-mail: firstname.lastname@example.org Web Site: www.PNM.com Link To Webcast: www.PNM.com/invest PNM Resources is an energy holding company based in Albuquerque, N.M. Its principal subsidiary is Public Service Company of New Mexico (PNM), the largest investor-owned utility in the state, serving more than 413,000 electric customers and 471,000 natural gas customers. The utility also markets power in the western United States. In July 2004, PNM Resources announced its proposed acquisition of TNP Enterprises, an energy holding company based in Fort Worth, Texas. If approved, the acquisition will expand PNM Resources' footprint in New Mexico and introduce the company to the competitive electric market in Texas. After the acquisition, PNM Resources' combined subsidiaries would provide energy to nearly 471,000 natural gas customers and nearly 725,000 electric customers in New Mexico and Texas. PNM Resources and its subsidiaries have a long history of community giving. Its community support and involvement focus on education, employee engagement, economic development and the environment. Company: Royal Gold Date of Presentation: March 1, 2005 Time of Presentation: 9:40 a.m. E.T. Investor Relations Contact: Karen Gross Phone: 303-575-6504 E-mail: email@example.com Web Site: www.royalgold.com Royal Gold, Inc. is the leading publicly-traded precious metals royalty company. Royal Gold owns and manages royalties on precious metals mines without incurring any ongoing capital or operating costs associated with an operating mining company. Through its royalty portfolio, Royal Gold provides investors with a unique opportunity to capture value in the precious metals sector. Additionally, Royal Gold provides its investors with valuable leverage to improving gold prices with sliding-scale royalties. The Company has also lowered its portfolio risk on the downside with fixed price royalties and floors on its sliding-scale royalties. Through its dividend policy and business strategy, Royal Gold strives to provide shareholders with a premium precious metals investment vehicle. The Company's royalty portfolio is designed to provide an excellent royalty-based risk profile, quality operating partners and assets, low corporate expenses, leverage to precious metal prices, and reserves and production growth potential to provide an attractive return on investment. Company: SpatiaLight, Inc. Date of Presentation: February 28, 2005 Time of Presentation: 12:30 Investor Relations Contact: Ted Banzhaf Phone: 415-883-1693 x132 E-mail: firstname.lastname@example.org Web Site: www.spatialight.com Link To Webcast: http://www.vcall.com/CEPage.asp?ID=90674 SpatiaLight, Inc. (Nasdaq:HDTV), is a leading developer and manufacturer of state-of-the-art high resolution liquid crystal on silicon (LCoS) microdisplay devices for use in High Definition televisions and rear projection monitors. The Company's proprietary SpatiaLight imagEngine(TM) microdisplays are intended to become the industry standard for the next generation of rear projection display devices, both in terms of price and performance. In July 2004, SpatiaLight entered into an agreement with LG Electronics for the sale of sets of 1920 x 1080p LCoS micrpdisplays for incorporation into high definition televisions. SpatiaLight currently has customers in South Korea, China and Taiwan, and is working with prospective customers in Japan and other parts of the Pacific Rim region. SpatiaLight recently announced that it is holding a ribbon cutting ceremony in March 2005 for the opening of its new mass production manufacturing facility located in South Korea. Company: Stratasys Inc. Date of Presentation: Tues., March 1, 2005 Time of Presentation: 9:40 a.m. ET Investor Relations Contact: Shane Glenn Phone: 952-294-3416 E-mail: email@example.com Web Site: www.Stratasys.com Link To Webcast: http://www.vcall.com/CEPage.asp?ID=90689 Stratasys Inc., Minneapolis, manufactures office-based rapid prototyping systems and 3D printers. According to Wohlers Report 2004, the company supplied 37 percent of all systems installed worldwide in 2003, making it the unit market leader. Stratasys patented the rapid prototyping process known as fused deposition modeling (FDM). The process creates functional models directly from 3D CAD files using ABS plastic, polycarbonate, and PPSF. The company holds 110 granted or pending rapid prototyping patents. Stratasys products are used in the aerospace, defense, automotive, medical, education, electronic, and consumer product industries. The company's systems are also used for rapid manufacturing and rapid tooling applications. For more information on the company, go to www.Stratasys.com. Company: Synthetic Blood International Date of Presentation: February 28 Time of Presentation: 9:00 a.m. EST Investor Relations Contact: Jody Cain or Brandi Floberg Phone: 310-691-7100 E-mail: firstname.lastname@example.org or email@example.com Web Site: www.sybd.com Link To Webcast: http://www.vcall.com/CEPage.asp?ID=90656 Synthetic Blood develops innovative pharmaceuticals and medical devices with oxygen therapeutic and continuous substrate monitoring technologies. The Company's products are based on perfluorocarbon (PFC) and biosensor technologies. Synthetic Blood's lead product candidate, Oyxcyte(TM), is being developed as a safe and effective alternative to transfused blood for use in surgical and other medical situations. Oxycyte is an oxygen-carrying intravenous emulsion that can carry 3-4X more oxygen than hemoglobin, making it an effective means of transporting oxygen to tissues and carbon dioxide to the lungs. Applications include stroke, myocardial infarction and certain malignant diseases. Oxycyte can be produced in quantity and administered cost effectively, while avoiding risks associated with animal blood-based products. In January 2005, Synthetic Blood opened patient enrollment in a Phase II Oxycyte study to evaluate the safety and efficacy of Oxycyte in preventing tissue hypoxia in orthopedic surgical patients. The Company plans to complete this trial and initiate two additional Phase II Oxycyte trials this year. Other products in the Company's pipeline include Fluorovent(TM), a liquid ventilator providing oxygen exchange fluid for facilitating the treatment of lung conditions, and a biosensor implant product that uses an enzyme process for measuring the glucose level in the blood stream. Company: Tripos, Inc. Date of Presentation: Monday, Feb. 28, 2005 Time of Presentation: 10:20 a.m. EST Investor Relations Contact: Lisa Osborne Phone: 425-638-7134 E-mail: firstname.lastname@example.org Web Site: www.tripos.com Link To Webcast: http://www.vcall.com/cepage.asp?id=90649 Tripos (Nasdaq:TRPS) combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. Tripos collaborates with clients to accelerate and improve the creation of life-enhancing products. Within Tripos' Discovery Informatics (DI) business, the company provides software products and consulting services to develop, manage, analyze and share critical drug discovery information. Within Tripos' Discovery Research (DR) business, Tripos' medicinal chemists and research scientists partner directly with clients in their research initiatives, leveraging state-of-the-art information technologies and research facilities. Headquartered in St. Louis, Mo., Tripos spans the world with global research operations and an international client base. Further information on Tripos can be found at http://www.tripos.com.
Note to Show Organizers: For information about adding your trade show, conference or event to http://www.tradeshownews.com contact Business Wire's Global Event Services Group at email@example.com.
CONTACT: Business Wire Global Event Services 310-820-9473 Ext. 602 -0- Feb/28/2005 12:00 GMT